CR 8020

Drug Profile

CR 8020

Alternative Names: Anti Flu Virus mAb40C7; CR-8020; Influenza monoclonal antibody 40C7; JNJ-54235051; Monoclonal antibody against influenza A viruses (CR8020) - Crucell

Latest Information Update: 05 May 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator AIMM Therapeutics
  • Developer Crucell
  • Class Antivirals; Monoclonal antibodies
  • Mechanism of Action Influenza virus haemagglutinin glycoprotein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Influenza A virus H3N2 subtype
  • No development reported Influenza A virus infections

Most Recent Events

  • 05 May 2016 CR 8020 is still in phase II trials for Influenza-A virus H3N2 subtype (Prevention, In volunteers) in United Kingdom (IV)
  • 05 May 2016 No development reported - Phase-I for Influenza-A virus infections in USA (IV)
  • 03 Mar 2014 Crucell terminates phase II trial in Influenza A virus infections in USA (NCT01992276)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top